STOCK TITAN

Cerus Corp. - CERS STOCK NEWS

Welcome to our dedicated news page for Cerus (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cerus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cerus's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.79%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.81%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
none
Cerus Corp.

Nasdaq:CERS

CERS Rankings

CERS Stock Data

317.25M
154.72M
2.53%
74.97%
3.24%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Concord

About CERS

cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.